Search - tctmd.com

Displaying 581 - 600 of 951

Sort: Relevancy | Date

Presentation TCT 2017

Worldwide Deaths and MI From Coronary Atherosclerosis: Scope of an Epidemic

Presenter: John A. Ambrose, Y. S. Chandrashekhar, James E. Muller

November 01, 2017

Presentation TCT 2017

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Presenter: Hiren Mistry, Michael A. Weber

October 31, 2017

Presentation TCT 2017

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Presenter: Hiren Mistry, Michael A. Weber, Michael Böhm

October 31, 2017

Presentation TCT 2017

TAP vs Culotte Stenting Beyond The Clinical Trials: A Different View

Presenter: Cihangir Kaymaz, Jeroen Vos, Armando Perez de Prado

October 31, 2017

Presentation TCT 2017

Representation of Women and Minorities in European Trials

Presenter: David P. Faxon, Cindy L. Grines, Angeles Alonso Garcia

October 31, 2017

Presentation TCT 2017

Strategies to Increase Enrollment of Women and Minorities Into Clinical Trials

Presenter: David P. Faxon, Cindy L. Grines, Roxana Mehran

October 31, 2017

Presentation TCT 2017

FDA Perspectives on Diversity in Clinical Trials

Presenter: David P. Faxon, Cindy L. Grines, Christopher J Popma

October 31, 2017

Presentation TCT 2017

Intelligence for Better Clinical Care (Imperative)

Presenter: Louis A. Cannon, Peter J. Fitzgerald, Juan F. Granada, Gopal Chopra

October 31, 2017

Presentation TCT 2017

Pacemaker Mediated Hypertension Treatment (BackBeat): First-in-Man Results and Ongoing Plans

Presenter: Elazer R. Edelman, Paul A. Sobotka, Karl-Heinz Kuck

October 30, 2017

Presentation TCT 2017

AV-Fistula Creation (ROX Coupler): Extended Follow-up Results and Next Steps

Presenter: Elazer R. Edelman, Paul A. Sobotka, Krishna J. Rocha-Singh

October 30, 2017

Presentation TCT 2017

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

Presenter: Elazer R. Edelman, Paul A. Sobotka

October 30, 2017

Presentation TCT 2017

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Presenter: Michael Böhm, Thomas F. Luscher, Robert S. Schwartz

October 30, 2017

Presentation TCT 2017

Diagnostic Mapping and Functional Assessment of the Renal Nerves: The Pythagoras Device

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Alcohol-Mediated Renal Denervation With a Higher-Dose: From the European Registry to Target BP 1

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Vessix RE-INFORCE Trial Update

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

Catheter-Based Ultrasound Renal Denervation: RADIANCE Trial Update

Presenter: Michael Böhm, Thomas F. Luscher, Laura Mauri

October 30, 2017

Presentation TCT 2017

KONAs WAVE IV Randomized Trial: Principal Results and Lessons Learned

Presenter: Michael Böhm, Thomas F. Luscher, Melvin D. Lobo

October 30, 2017

Presentation TCT 2017

First Results From the SPYRAL Hypertension Program (OFF-MED Study)

Presenter: Michael Böhm, Thomas F. Luscher

October 30, 2017

Presentation TCT 2017

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Advertisement

Worldwide Deaths and MI From Coronary Atherosclerosis: Scope of an Epidemic

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

TAP vs Culotte Stenting Beyond The Clinical Trials: A Different View

Representation of Women and Minorities in European Trials

Strategies to Increase Enrollment of Women and Minorities Into Clinical Trials

FDA Perspectives on Diversity in Clinical Trials

Intelligence for Better Clinical Care (Imperative)

Pacemaker Mediated Hypertension Treatment (BackBeat): First-in-Man Results and Ongoing Plans

AV-Fistula Creation (ROX Coupler): Extended Follow-up Results and Next Steps

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Diagnostic Mapping and Functional Assessment of the Renal Nerves: The Pythagoras Device

Alcohol-Mediated Renal Denervation With a Higher-Dose: From the European Registry to Target BP 1

Vessix RE-INFORCE Trial Update

Catheter-Based Ultrasound Renal Denervation: RADIANCE Trial Update

KONAs WAVE IV Randomized Trial: Principal Results and Lessons Learned

First Results From the SPYRAL Hypertension Program (OFF-MED Study)

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content